Compare Regeneron Pharmaceuticals Inc (REGN) vs Ulta Beauty Inc (ULTA) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.

ULTA stock trades at $545.48, down 0.33% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings that beat estimates and raised its 2026 outlook, driven by e-commerce growth. Key financials show robust profitability with a 9.34% net income margin and 46.12% ROE, though revenue growth has moderated recently. Analyst sentiment is positive with a consensus price target of $624.93, implying potential upside from current levels.

The outlook for ULTA is favorable, supported by raised guidance and strategic initiatives in omnichannel and wellness categories. Investment opportunities include valuation expansion if execution meets raised expectations. Key risks include margin pressure from promotions, flat store traffic, and competitive pressures in the beauty retail space that could challenge future earnings growth.